<?xml version="1.0" encoding="UTF-8"?>
<Label drug="blincyto" track="TAC2017_ADR">
  <Text>
    <Section name="adverse reactions" id="S1">    6. ADVERSE REACTIONS

  The following adverse reactions are discussed in greater detail in other sections of the label:    



 *  Cytokine Release Syndrome [see Warnings and Precautions (  5.1  )]  
 *  Neurological Toxicities [see Warnings and Precautions (  5.2  )]  
 *  Infections [see Warnings and Precautions (  5.3  )]  
 *  Tumor Lysis Syndrome [see Warnings and Precautions (  5.4  )]  
 *  Neutropenia and Febrile Neutropenia [see Warnings and Precautions (  5.5  )]  
 *  Effects on Ability to Drive and Use Machines [see Warnings and Precautions (  5.6  )]  
 *  Elevated Liver Enzymes [see Warnings and Precautions (  5.7  )]  
 *  Leukoencephalopathy [see Warnings and Precautions (  5.8  )]  
 *  Preparation and Administration Errors [see Warnings and Precautions (  5.9  )]  
   *   The most common adverse reactions (&gt;= 20%) were pyrexia, headache, peripheral edema, febrile neutropenia, nausea, hypokalemia, tremor, rash, and constipation. (  6.1  )
 
      EXCERPT:   

}}        To report SUSPECTED ADVERSE REACTIONS, contact Amgen Inc. at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.        



 

  6.1     Clinical Trials Experience

  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.



 The safety data described in this section reflect exposure to BLINCYTO in clinical trials in which 212 patients with relapsed or refractory ALL received up to 28 mcg/day. All patients received at least one dose of BLINCYTO. The median age of the study population was 37 years (range: 18 to 79 years), 63% were male, 79% were White, 3% were Asian, and 3% were Black or African American. 



 The most common adverse reactions (&gt;= 20%) were pyrexia (62%), headache (36%), peripheral edema (25%), febrile neutropenia (25%), nausea (25%), hypokalemia (23%), and constipation (20%).



 Serious adverse reactions were reported in 65% of patients. The most common serious adverse reactions (&gt;= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.



 Adverse reactions of Grade 3 or higher were reported in 80% of patients. Discontinuation of therapy due to adverse reactions occurred in 18% of patients treated with BLINCYTO. The adverse reactions reported most frequently as the reason for discontinuation of treatment included encephalopathy and sepsis. Fatal adverse events occurred in 15% of patients. The majority of these events were infections. No fatal adverse events occurred on treatment among patients in remission.



 The adverse reactions with &gt;= 10% incidence for any grade or &gt;= 5% incidence for Grade 3 or higher are summarized in Table 2.



 Table 2. Adverse Reactions With &gt;= 10% Incidence for Any Grade or &gt;= 5% Incidence for Grade 3 or Higher (N = 212) 
  Adverse Reaction    Any GradeGrading based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0(%)    Grade 3 or Higher(%)    
  
  Blood and lymphatic system disorders       Febrile neutropenia     Anemia     Neutropenia     Thrombocytopenia     Leukopenia             251816119         23131588    
  Gastrointestinal disorders       Nausea     Constipation     DiarrheaDiarrhea includes the following terms: colitis, diarrhea, enteritis, and neutropenic colitis.     Abdominal pain     Vomiting             2520201513        0&lt; 1120    
  General disorders and administration site conditions       Pyrexia     Peripheral edema     Fatigue     Chills     Chest pain              6225171511        7&lt; 1101    
  Immune system disorders       Cytokine release syndrome             11        1    
  Infections and infestations       Other pathogen infections     Bacterial infections     Fungal infections     Viral infections     Pneumonia     Sepsis        4419151397        25127486    
  Investigations     Increased alanine aminotransferase     Increased aspartate aminotransferase     Increased weight        121111        640    
  Metabolism and nutrition disorders       Hypokalemia     Hypomagnesemia     Hyperglycemia     Decreased appetite     Hypophosphatemia              231211106           60735    
  Musculoskeletal and connective tissue disorders       Back pain     Pain in extremity     Bone pain     Arthralgia             14121110        2132    
  Nervous system disorders       Headache     TremorTremor includes the following terms: resting tremor and tremor.     Dizziness            362014       31&lt; 1    
  Psychiatric disorders       Insomnia            15        0    
  Respiratory, thoracic, and mediastinal disorders       Cough     DyspneaDyspnea includes the following terms: acute respiratory failure, bronchial hyperactivity, bronchospasm, dyspnea, dyspnea exertional, respiratory distress, respiratory failure, and wheezing.              1915        05    
  Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.        21       2    
  Vascular disorders       Hypotension     Hypertension           118       25    
         Additional important adverse reactions that did not meet the threshold criteria for inclusion in Table 2 were:
 

   Blood and lymphatic system disorders:  leukocytosis (2%), lymphopenia (1%)



   Cardiac disorders:  tachycardia (8%)



   General disorders and administration site conditions:  edema (5%)



   Immune system disorders:  cytokine storm (1%)



   Investigations:  decreased immunoglobulins (9%), increased blood bilirubin (8%), increased gamma-glutamyl-transferase (6%), increased liver enzymes (1%)



   Metabolism and nutrition disorders:  tumor lysis syndrome (4%), hypoalbuminemia (4%)



   Nervous system disorders:  encephalopathy (5%), paresthesia (5%), aphasia (4%), convulsion (2%), memory impairment (2%), cognitive disorder (1%), speech disorder (&lt; 1%)



   Psychiatric disorders:  confusion (7%), disorientation (3%)



   Vascular disorders    :  capillary leak syndrome (&lt; 1%).



 Hypersensitivity reactions related to BLINCYTO treatment were hypersensitivity (1%) and bronchospasm (&lt; 1%).



   6.2     Immunogenicity

  As with all therapeutic proteins, there is potential for immunogenicity. The immunogenicity of BLINCYTO has been evaluated using either an electrochemiluminescence detection technology (ECL) or an enzyme-linked immunosorbent assay (ELISA) screening immunoassay for the detection of binding anti-blinatumomab antibodies. For patients whose sera tested positive in the screening immunoassay, an  in vitro  biological assay was performed to detect neutralizing antibodies.  



 In clinical studies, less than 1% of patients treated with BLINCYTO tested positive for binding anti-blinatumomab antibodies. All patients who tested positive for binding antibodies also tested positive for neutralizing anti-blinatumomab antibodies.



 Anti-blinatumomab antibody formation may affect pharmacokinetics of BLINCYTO. No association was seen between antibody development and development of adverse events. 



 If formation of anti-blinatumomab antibodies with a clinically significant effect is suspected, contact Amgen at 1-800-77-AMGEN (1-800-772-6436) to discuss antibody testing.



 The detection of anti-blinatumomab antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to blinatumomab with the incidence of antibodies to other products may be misleading.
</Section>
    <Section name="boxed warnings" id="S2">

    BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and

NEUROLOGICAL TOXICITIES

    WARNING: CYTOKINE RELEASE SYNDROME and

NEUROLOGICAL TOXICITIES  

    *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO. Interrupt or discontinue BLINCYTO as recommended. [See Dosage and Administration (2.3), Warnings and Precautions (5.1)].     
 *  Neurological toxicities, which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO. Interrupt or discontinue BLINCYTO as recommended. [See Dosage and Administration (2.3), Warnings and Precautions (5.2)]. 
      EXCERPT:     WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES      See full prescribing information for complete boxed warning.    
 

 *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO. Interrupt or discontinue BLINCYTO as recommended. (2.3), (5.1) 
 *  Neurological toxicities, which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO. Interrupt or discontinue BLINCYTO as recommended. (2.3), (5.2) 
</Section>
    <Section name="warnings and precautions" id="S3">    5. WARNINGS AND PRECAUTIONS



   EXCERPT:    *  Infections: Monitor patients for signs or symptoms and treat appropriately. (  5.3  ) 
 *  Effects on Ability to Drive and Use Machines: Advise patients to refrain from driving and engaging in hazardous occupations or activities such as operating heavy or potentially dangerous machinery while BLINCYTO is being administered. (  5.6  ) 
 *  Preparation and Administration Errors: Strictly follow instructions for preparation (including admixing) and administration. (  5.9  ) 
    
 

   5.1     Cytokine Release Syndrome



  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO. 



 Infusion reactions have occurred with the BLINCYTO infusion and may be clinically indistinguishable from manifestations of CRS .   



 Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation. Life-threatening or fatal CRS was infrequently reported in patients receiving BLINCYTO. In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS. 



 Patients should be closely monitored for signs or symptoms of these events. Management of these events may require either temporary interruption or discontinuation of BLINCYTO [see Dosage and Administration (  2.3  )]  .



    5.2     Neurological Toxicities



  In patients receiving BLINCYTO in clinical trials, neurological toxicities have occurred in approximately 50% of patients. The median time to onset of any neurological toxicity was 7 days. Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders. The majority of events resolved following interruption of BLINCYTO, but some resulted in treatment discontinuation. 



 Monitor patients receiving BLINCYTO for signs and symptoms of neurological toxicities, and interrupt or discontinue BLINCYTO as recommended [see Dosage and Administration (  2.3  )].     



    5.3     Infections



  In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal. As appropriate, administer prophylactic antibiotics and employ surveillance testing during treatment with BLINCYTO.  Monitor patients for signs and symptoms of infection and treat appropriately.



    5.4     Tumor Lysis Syndrome



  Tumor lysis syndrome (TLS), which may be life-threatening or fatal, has been observed in patients receiving BLINCYTO. Appropriate prophylactic measures, including pretreatment nontoxic cytoreduction and on-treatment hydration, should be used for the prevention of TLS during BLINCYTO treatment. Monitor for signs or symptoms of TLS. Management of these events may require either temporary interruption or discontinuation of BLINCYTO [see Dosage and Administration (  2.3  )]  .



    5.5     Neutropenia and Febrile Neutropenia



  Neutropenia and febrile neutropenia, including life-threatening cases, have been observed in patients receiving BLINCYTO. Monitor laboratory parameters (including, but not limited to, white blood cell count and absolute neutrophil count) during BLINCYTO infusion. Interrupt BLINCYTO if prolonged neutropenia occurs. 



    5.6     Effects on Ability to Drive and Use Machines



  Due to the potential for neurologic events, including seizures, patients receiving BLINCYTO are at risk for loss of consciousness [see Warnings and Precautions (  5.2  )]  . Advise patients to refrain from driving and engaging in hazardous occupations or activities such as operating heavy or potentially dangerous machinery while BLINCYTO is being administered. 



    5.7     Elevated Liver Enzymes



  Treatment with BLINCYTO was associated with transient elevations in liver enzymes. Although the majority of these events were observed in the setting of CRS, some were observed outside of this setting. For these events, the median time to onset was 15 days.  In patients receiving BLINCYTO in clinical trials, Grade 3 or greater elevations in liver enzymes occurred in approximately 6% of patients outside the setting of CRS and resulted in treatment discontinuation in less than 1% of patients.



 Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), and total blood bilirubin prior to the start of and during BLINCYTO treatment. Interrupt BLINCYTO if the transaminases rise to greater than 5 times the upper limit of normal or if bilirubin rises to more than 3 times the upper limit of normal .  



    5.8     Leukoencephalopathy



  Cranial magnetic resonance imaging (MRI) changes showing leukoencephalopathy have been observed in patients receiving BLINCYTO, especially in patients with prior treatment with cranial irradiation and antileukemic chemotherapy (including systemic high-dose methotrexate or intrathecal cytarabine). The clinical significance of these imaging changes is unknown.    



    5.9     Preparation and Administration Errors



  Preparation and administration errors have occurred with BLINCYTO treatment. Follow instructions for preparation (including admixing) and administration strictly to minimize medication errors (including underdose and overdose) [see Dosage and Administration (  2.2  ) and (  2.4  )]  .
</Section>
  </Text>
  <Mentions>
    <Mention id="M1" section="S1" type="AdverseReaction" start="135" len="25" str="Cytokine Release Syndrome" />
    <Mention id="M2" section="S1" type="AdverseReaction" start="208" len="23" str="Neurological Toxicities" />
    <Mention id="M3" section="S1" type="AdverseReaction" start="279" len="10" str="Infections" />
    <Mention id="M4" section="S1" type="AdverseReaction" start="337" len="20" str="Tumor Lysis Syndrome" />
    <Mention id="M5" section="S1" type="AdverseReaction" start="405" len="11" str="Neutropenia" />
    <Mention id="M6" section="S1" type="AdverseReaction" start="421" len="19" str="Febrile Neutropenia" />
    <Mention id="M7" section="S1" type="AdverseReaction" start="488" len="27" str="Effects on Ability to Drive" />
    <Mention id="M8" section="S1" type="AdverseReaction" start="488,520" len="21,12" str="Effects on Ability to Use Machines" />
    <Mention id="M9" section="S1" type="AdverseReaction" start="580" len="22" str="Elevated Liver Enzymes" />
    <Mention id="M10" section="S1" type="AdverseReaction" start="650" len="19" str="Leukoencephalopathy" />
    <Mention id="M11" section="S1" type="AdverseReaction" start="853" len="7" str="pyrexia" />
    <Mention id="M12" section="S1" type="AdverseReaction" start="862" len="8" str="headache" />
    <Mention id="M13" section="S1" type="AdverseReaction" start="872" len="16" str="peripheral edema" />
    <Mention id="M14" section="S1" type="AdverseReaction" start="890" len="19" str="febrile neutropenia" />
    <Mention id="M15" section="S1" type="AdverseReaction" start="911" len="6" str="nausea" />
    <Mention id="M16" section="S1" type="AdverseReaction" start="919" len="11" str="hypokalemia" />
    <Mention id="M17" section="S1" type="AdverseReaction" start="932" len="6" str="tremor" />
    <Mention id="M18" section="S1" type="AdverseReaction" start="940" len="4" str="rash" />
    <Mention id="M19" section="S1" type="AdverseReaction" start="950" len="12" str="constipation" />
    <Mention id="M20" section="S1" type="AdverseReaction" start="1909" len="7" str="pyrexia" />
    <Mention id="M21" section="S1" type="AdverseReaction" start="1924" len="8" str="headache" />
    <Mention id="M22" section="S1" type="AdverseReaction" start="1940" len="16" str="peripheral edema" />
    <Mention id="M23" section="S1" type="AdverseReaction" start="1964" len="19" str="febrile neutropenia" />
    <Mention id="M24" section="S1" type="AdverseReaction" start="1991" len="6" str="nausea" />
    <Mention id="M25" section="S1" type="AdverseReaction" start="2005" len="11" str="hypokalemia" />
    <Mention id="M26" section="S1" type="AdverseReaction" start="2028" len="12" str="constipation" />
    <Mention id="M27" section="S1" type="AdverseReaction" start="2171" len="19" str="febrile neutropenia" />
    <Mention id="M28" section="S1" type="AdverseReaction" start="2192" len="7" str="pyrexia" />
    <Mention id="M29" section="S1" type="AdverseReaction" start="2201" len="9" str="pneumonia" />
    <Mention id="M30" section="S1" type="AdverseReaction" start="2212" len="6" str="sepsis" />
    <Mention id="M31" section="S1" type="AdverseReaction" start="2220" len="11" str="neutropenia" />
    <Mention id="M32" section="S1" type="AdverseReaction" start="2233" len="24" str="device-related infection" />
    <Mention id="M33" section="S1" type="AdverseReaction" start="2259" len="6" str="tremor" />
    <Mention id="M34" section="S1" type="AdverseReaction" start="2267" len="14" str="encephalopathy" />
    <Mention id="M35" section="S1" type="AdverseReaction" start="2283" len="9" str="infection" />
    <Mention id="M36" section="S1" type="AdverseReaction" start="2294" len="8" str="overdose" />
    <Mention id="M37" section="S1" type="AdverseReaction" start="2304" len="9" str="confusion" />
    <Mention id="M38" section="S1" type="AdverseReaction" start="2316" len="26" str="Staphylococcal bacteremia" />
    <Mention id="M39" section="S1" type="AdverseReaction" start="2348" len="8" str="headache" />
    <Mention id="M40" section="S1" type="AdverseReaction" start="2641" len="14" str="encephalopathy" />
    <Mention id="M41" section="S1" type="AdverseReaction" start="2660" len="6" str="sepsis" />
    <Mention id="M42" section="S1" type="AdverseReaction" start="2668" len="5" str="Fatal" />
    <Mention id="M43" section="S1" type="AdverseReaction" start="2752" len="10" str="infections" />
    <Mention id="M44" section="S1" type="Negation" start="2764" len="2" str="No" />
    <Mention id="M45" section="S1" type="AdverseReaction" start="2767" len="5" str="fatal" />
    <Mention id="M46" section="S1" type="AdverseReaction" start="3286" len="19" str="Febrile neutropenia" />
    <Mention id="M47" section="S1" type="AdverseReaction" start="3310" len="6" str="Anemia" />
    <Mention id="M48" section="S1" type="AdverseReaction" start="3321" len="11" str="Neutropenia" />
    <Mention id="M49" section="S1" type="AdverseReaction" start="3337" len="16" str="Thrombocytopenia" />
    <Mention id="M50" section="S1" type="AdverseReaction" start="3358" len="10" str="Leukopenia" />
    <Mention id="M51" section="S1" type="AdverseReaction" start="3447" len="6" str="Nausea" />
    <Mention id="M52" section="S1" type="AdverseReaction" start="3458" len="12" str="Constipation" />
    <Mention id="M53" section="S1" type="AdverseReaction" start="3475" len="8" str="Diarrhea" />
    <Mention id="M54" section="S1" type="AdverseReaction" start="3483" len="8" str="Diarrhea" />
    <Mention id="M55" section="S1" type="AdverseReaction" start="3522" len="7" str="colitis" />
    <Mention id="M56" section="S1" type="AdverseReaction" start="3531" len="8" str="diarrhea" />
    <Mention id="M57" section="S1" type="AdverseReaction" start="3541" len="9" str="enteritis" />
    <Mention id="M58" section="S1" type="AdverseReaction" start="3556" len="19" str="neutropenic colitis" />
    <Mention id="M59" section="S1" type="AdverseReaction" start="3581" len="14" str="Abdominal pain" />
    <Mention id="M60" section="S1" type="AdverseReaction" start="3600" len="8" str="Vomiting" />
    <Mention id="M61" section="S1" type="AdverseReaction" start="3712" len="7" str="Pyrexia" />
    <Mention id="M62" section="S1" type="AdverseReaction" start="3724" len="16" str="Peripheral edema" />
    <Mention id="M63" section="S1" type="AdverseReaction" start="3745" len="7" str="Fatigue" />
    <Mention id="M64" section="S1" type="AdverseReaction" start="3757" len="6" str="Chills" />
    <Mention id="M65" section="S1" type="AdverseReaction" start="3768" len="10" str="Chest pain" />
    <Mention id="M66" section="S1" type="AdverseReaction" start="3854" len="25" str="Cytokine release syndrome" />
    <Mention id="M67" section="S1" type="AdverseReaction" start="3959" len="10" str="infections" />
    <Mention id="M68" section="S1" type="AdverseReaction" start="3974" len="20" str="Bacterial infections" />
    <Mention id="M69" section="S1" type="AdverseReaction" start="3999" len="17" str="Fungal infections" />
    <Mention id="M70" section="S1" type="AdverseReaction" start="4021" len="16" str="Viral infections" />
    <Mention id="M71" section="S1" type="AdverseReaction" start="4042" len="9" str="Pneumonia" />
    <Mention id="M72" section="S1" type="AdverseReaction" start="4056" len="6" str="Sepsis" />
    <Mention id="M73" section="S1" type="AdverseReaction" start="4122" len="34" str="Increased alanine aminotransferase" />
    <Mention id="M74" section="S1" type="AdverseReaction" start="4161" len="36" str="Increased aspartate aminotransferase" />
    <Mention id="M75" section="S1" type="AdverseReaction" start="4202" len="16" str="Increased weight" />
    <Mention id="M76" section="S1" type="AdverseReaction" start="4291" len="11" str="Hypokalemia" />
    <Mention id="M77" section="S1" type="AdverseReaction" start="4307" len="14" str="Hypomagnesemia" />
    <Mention id="M78" section="S1" type="AdverseReaction" start="4326" len="13" str="Hyperglycemia" />
    <Mention id="M79" section="S1" type="AdverseReaction" start="4344" len="18" str="Decreased appetite" />
    <Mention id="M80" section="S1" type="AdverseReaction" start="4367" len="16" str="Hypophosphatemia" />
    <Mention id="M81" section="S1" type="AdverseReaction" start="4483" len="9" str="Back pain" />
    <Mention id="M82" section="S1" type="AdverseReaction" start="4497" len="17" str="Pain in extremity" />
    <Mention id="M83" section="S1" type="AdverseReaction" start="4519" len="9" str="Bone pain" />
    <Mention id="M84" section="S1" type="AdverseReaction" start="4533" len="10" str="Arthralgia" />
    <Mention id="M85" section="S1" type="AdverseReaction" start="4614" len="8" str="Headache" />
    <Mention id="M86" section="S1" type="AdverseReaction" start="4627" len="6" str="Tremor" />
    <Mention id="M87" section="S1" type="AdverseReaction" start="4633" len="6" str="Tremor" />
    <Mention id="M88" section="S1" type="AdverseReaction" start="4670" len="14" str="resting tremor" />
    <Mention id="M89" section="S1" type="AdverseReaction" start="4689" len="6" str="tremor" />
    <Mention id="M90" section="S1" type="AdverseReaction" start="4701" len="9" str="Dizziness" />
    <Mention id="M91" section="S1" type="AdverseReaction" start="4775" len="8" str="Insomnia" />
    <Mention id="M92" section="S1" type="AdverseReaction" start="4868" len="5" str="Cough" />
    <Mention id="M93" section="S1" type="AdverseReaction" start="4878" len="7" str="Dyspnea" />
    <Mention id="M94" section="S1" type="AdverseReaction" start="4885" len="7" str="Dyspnea" />
    <Mention id="M95" section="S1" type="AdverseReaction" start="4923" len="25" str="acute respiratory failure" />
    <Mention id="M96" section="S1" type="AdverseReaction" start="4950" len="23" str="bronchial hyperactivity" />
    <Mention id="M97" section="S1" type="AdverseReaction" start="4975" len="12" str="bronchospasm" />
    <Mention id="M98" section="S1" type="AdverseReaction" start="4989" len="7" str="dyspnea" />
    <Mention id="M99" section="S1" type="AdverseReaction" start="4998" len="18" str="dyspnea exertional" />
    <Mention id="M100" section="S1" type="AdverseReaction" start="5018" len="20" str="respiratory distress" />
    <Mention id="M101" section="S1" type="AdverseReaction" start="5040" len="19" str="respiratory failure" />
    <Mention id="M102" section="S1" type="AdverseReaction" start="5065" len="8" str="wheezing" />
    <Mention id="M103" section="S1" type="AdverseReaction" start="5154" len="4" str="Rash" />
    <Mention id="M104" section="S1" type="AdverseReaction" start="5158" len="4" str="Rash" />
    <Mention id="M105" section="S1" type="AdverseReaction" start="5193" len="8" str="erythema" />
    <Mention id="M106" section="S1" type="AdverseReaction" start="5203" len="4" str="rash" />
    <Mention id="M107" section="S1" type="AdverseReaction" start="5209" len="17" str="erythematous rash" />
    <Mention id="M108" section="S1" type="AdverseReaction" start="5228" len="16" str="generalized rash" />
    <Mention id="M109" section="S1" type="AdverseReaction" start="5246" len="12" str="macular rash" />
    <Mention id="M110" section="S1" type="AdverseReaction" start="5260" len="19" str="maculo-papular rash" />
    <Mention id="M111" section="S1" type="AdverseReaction" start="5281" len="12" str="papular rash" />
    <Mention id="M112" section="S1" type="AdverseReaction" start="5299" len="14" str="vesicular rash" />
    <Mention id="M113" section="S1" type="AdverseReaction" start="5364" len="11" str="Hypotension" />
    <Mention id="M114" section="S1" type="AdverseReaction" start="5380" len="12" str="Hypertension" />
    <Mention id="M115" section="S1" type="AdverseReaction" start="5585" len="12" str="leukocytosis" />
    <Mention id="M116" section="S1" type="AdverseReaction" start="5604" len="11" str="lymphopenia" />
    <Mention id="M117" section="S1" type="AdverseReaction" start="5647" len="11" str="tachycardia" />
    <Mention id="M118" section="S1" type="AdverseReaction" start="5725" len="5" str="edema" />
    <Mention id="M119" section="S1" type="AdverseReaction" start="5768" len="14" str="cytokine storm" />
    <Mention id="M120" section="S1" type="AdverseReaction" start="5811" len="25" str="decreased immunoglobulins" />
    <Mention id="M121" section="S1" type="AdverseReaction" start="5843" len="25" str="increased blood bilirubin" />
    <Mention id="M122" section="S1" type="AdverseReaction" start="5875" len="36" str="increased gamma-glutamyl-transferase" />
    <Mention id="M123" section="S1" type="AdverseReaction" start="5918" len="23" str="increased liver enzymes" />
    <Mention id="M124" section="S1" type="AdverseReaction" start="5990" len="20" str="tumor lysis syndrome" />
    <Mention id="M125" section="S1" type="AdverseReaction" start="6017" len="15" str="hypoalbuminemia" />
    <Mention id="M126" section="S1" type="AdverseReaction" start="6071" len="14" str="encephalopathy" />
    <Mention id="M127" section="S1" type="AdverseReaction" start="6092" len="11" str="paresthesia" />
    <Mention id="M128" section="S1" type="AdverseReaction" start="6110" len="7" str="aphasia" />
    <Mention id="M129" section="S1" type="AdverseReaction" start="6124" len="10" str="convulsion" />
    <Mention id="M130" section="S1" type="AdverseReaction" start="6141" len="17" str="memory impairment" />
    <Mention id="M131" section="S1" type="AdverseReaction" start="6165" len="18" str="cognitive disorder" />
    <Mention id="M132" section="S1" type="AdverseReaction" start="6190" len="15" str="speech disorder" />
    <Mention id="M133" section="S1" type="AdverseReaction" start="6243" len="9" str="confusion" />
    <Mention id="M134" section="S1" type="AdverseReaction" start="6259" len="14" str="disorientation" />
    <Mention id="M135" section="S1" type="AdverseReaction" start="6310" len="23" str="capillary leak syndrome" />
    <Mention id="M136" section="S1" type="AdverseReaction" start="6346" len="26" str="Hypersensitivity reactions" />
    <Mention id="M137" section="S1" type="AdverseReaction" start="6408" len="16" str="hypersensitivity" />
    <Mention id="M138" section="S1" type="AdverseReaction" start="6434" len="12" str="bronchospasm" />
    <Mention id="M139" section="S2" type="AdverseReaction" start="30" len="25" str="CYTOKINE RELEASE SYNDROME" />
    <Mention id="M140" section="S2" type="AdverseReaction" start="61" len="23" str="NEUROLOGICAL TOXICITIES" />
    <Mention id="M141" section="S2" type="AdverseReaction" start="99" len="25" str="CYTOKINE RELEASE SYNDROME" />
    <Mention id="M142" section="S2" type="AdverseReaction" start="130" len="23" str="NEUROLOGICAL TOXICITIES" />
    <Mention id="M143" section="S2" type="AdverseReaction" start="164" len="25" str="Cytokine Release Syndrome" />
    <Mention id="M144" section="S2" type="AdverseReaction" start="164" len="25" str="Cytokine Release Syndrome" />
    <Mention id="M145" section="S2" type="AdverseReaction" start="191" len="3" str="CRS" />
    <Mention id="M146" section="S2" type="AdverseReaction" start="191" len="3" str="CRS" />
    <Mention id="M147" section="S2" type="Factor" start="203" len="3" str="may" />
    <Mention id="M148" section="S2" type="Severity" start="210" len="16" str="life-threatening" />
    <Mention id="M149" section="S2" type="AdverseReaction" start="230" len="5" str="fatal" />
    <Mention id="M150" section="S2" type="AdverseReaction" start="408" len="23" str="Neurological toxicities" />
    <Mention id="M151" section="S2" type="AdverseReaction" start="408" len="23" str="Neurological toxicities" />
    <Mention id="M152" section="S2" type="Factor" start="439" len="3" str="may" />
    <Mention id="M153" section="S2" type="Severity" start="446" len="6" str="severe" />
    <Mention id="M154" section="S2" type="Severity" start="454" len="16" str="life-threatening" />
    <Mention id="M155" section="S2" type="AdverseReaction" start="475" len="5" str="fatal" />
    <Mention id="M156" section="S2" type="AdverseReaction" start="673" len="25" str="CYTOKINE RELEASE SYNDROME" />
    <Mention id="M157" section="S2" type="AdverseReaction" start="703" len="23" str="NEUROLOGICAL TOXICITIES" />
    <Mention id="M158" section="S2" type="AdverseReaction" start="804" len="25" str="Cytokine Release Syndrome" />
    <Mention id="M159" section="S2" type="AdverseReaction" start="804" len="25" str="Cytokine Release Syndrome" />
    <Mention id="M160" section="S2" type="AdverseReaction" start="831" len="3" str="CRS" />
    <Mention id="M161" section="S2" type="AdverseReaction" start="831" len="3" str="CRS" />
    <Mention id="M162" section="S2" type="Factor" start="843" len="3" str="may" />
    <Mention id="M163" section="S2" type="Severity" start="850" len="16" str="life-threatening" />
    <Mention id="M164" section="S2" type="AdverseReaction" start="870" len="5" str="fatal" />
    <Mention id="M165" section="S2" type="AdverseReaction" start="986" len="23" str="Neurological toxicities" />
    <Mention id="M166" section="S2" type="AdverseReaction" start="986" len="23" str="Neurological toxicities" />
    <Mention id="M167" section="S2" type="Factor" start="1017" len="3" str="may" />
    <Mention id="M168" section="S2" type="Severity" start="1024" len="6" str="severe" />
    <Mention id="M169" section="S2" type="Severity" start="1032" len="16" str="life-threatening" />
    <Mention id="M170" section="S2" type="AdverseReaction" start="1053" len="5" str="fatal" />
    <Mention id="M171" section="S3" type="AdverseReaction" start="53" len="10" str="Infections" />
    <Mention id="M172" section="S3" type="AdverseReaction" start="144" len="27" str="Effects on Ability to Drive" />
    <Mention id="M173" section="S3" type="AdverseReaction" start="144,176" len="21,12" str="Effects on Ability to Use Machines" />
    <Mention id="M174" section="S3" type="AdverseReaction" start="580" len="25" str="Cytokine Release Syndrome" />
    <Mention id="M175" section="S3" type="AdverseReaction" start="580" len="25" str="Cytokine Release Syndrome" />
    <Mention id="M176" section="S3" type="AdverseReaction" start="607" len="3" str="CRS" />
    <Mention id="M177" section="S3" type="AdverseReaction" start="607" len="3" str="CRS" />
    <Mention id="M178" section="S3" type="Factor" start="619" len="3" str="may" />
    <Mention id="M179" section="S3" type="Severity" start="626" len="16" str="life-threatening" />
    <Mention id="M180" section="S3" type="AdverseReaction" start="646" len="5" str="fatal" />
    <Mention id="M181" section="S3" type="AdverseReaction" start="699" len="18" str="Infusion reactions" />
    <Mention id="M182" section="S3" type="AdverseReaction" start="886" len="3" str="CRS" />
    <Mention id="M183" section="S3" type="AdverseReaction" start="899" len="7" str="pyrexia" />
    <Mention id="M184" section="S3" type="AdverseReaction" start="908" len="8" str="headache" />
    <Mention id="M185" section="S3" type="AdverseReaction" start="918" len="6" str="nausea" />
    <Mention id="M186" section="S3" type="AdverseReaction" start="926" len="8" str="asthenia" />
    <Mention id="M187" section="S3" type="AdverseReaction" start="936" len="11" str="hypotension" />
    <Mention id="M188" section="S3" type="AdverseReaction" start="949" len="34" str="increased alanine aminotransferase" />
    <Mention id="M189" section="S3" type="AdverseReaction" start="985" len="36" str="increased aspartate aminotransferase" />
    <Mention id="M190" section="S3" type="AdverseReaction" start="1027" len="25" str="increased total bilirubin" />
    <Mention id="M191" section="S3" type="Severity" start="1113" len="16" str="Life-threatening" />
    <Mention id="M192" section="S3" type="AdverseReaction" start="1133" len="5" str="fatal" />
    <Mention id="M193" section="S3" type="AdverseReaction" start="1139" len="3" str="CRS" />
    <Mention id="M194" section="S3" type="AdverseReaction" start="1139" len="3" str="CRS" />
    <Mention id="M195" section="S3" type="AdverseReaction" start="1216" len="38" str="disseminated intravascular coagulation" />
    <Mention id="M196" section="S3" type="AdverseReaction" start="1256" len="3" str="DIC" />
    <Mention id="M197" section="S3" type="AdverseReaction" start="1262" len="23" str="capillary leak syndrome" />
    <Mention id="M198" section="S3" type="AdverseReaction" start="1287" len="3" str="CLS" />
    <Mention id="M199" section="S3" type="AdverseReaction" start="1297" len="34" str="hemophagocytic lymphohistiocytosis" />
    <Mention id="M200" section="S3" type="AdverseReaction" start="1332" len="30" str="macrophage activation syndrome" />
    <Mention id="M201" section="S3" type="AdverseReaction" start="1364" len="3" str="HLH" />
    <Mention id="M202" section="S3" type="AdverseReaction" start="1368" len="3" str="MAS" />
    <Mention id="M203" section="S3" type="AdverseReaction" start="1410" len="3" str="CRS" />
    <Mention id="M204" section="S3" type="AdverseReaction" start="1736" len="23" str="neurological toxicities" />
    <Mention id="M205" section="S3" type="Severity" start="1874" len="7" str="Grade 3" />
    <Mention id="M206" section="S3" type="Severity" start="1893" len="6" str="severe" />
    <Mention id="M207" section="S3" type="Severity" start="1901" len="16" str="life-threatening" />
    <Mention id="M208" section="S3" type="AdverseReaction" start="1922" len="5" str="fatal" />
    <Mention id="M209" section="S3" type="AdverseReaction" start="1929" len="23" str="neurological toxicities" />
    <Mention id="M210" section="S3" type="AdverseReaction" start="2056" len="14" str="encephalopathy" />
    <Mention id="M211" section="S3" type="AdverseReaction" start="2072" len="11" str="convulsions" />
    <Mention id="M212" section="S3" type="AdverseReaction" start="2085" len="16" str="speech disorders" />
    <Mention id="M213" section="S3" type="AdverseReaction" start="2103" len="29" str="disturbances in consciousness" />
    <Mention id="M214" section="S3" type="AdverseReaction" start="2134" len="9" str="confusion" />
    <Mention id="M215" section="S3" type="AdverseReaction" start="2148" len="14" str="disorientation" />
    <Mention id="M216" section="S3" type="AdverseReaction" start="2168,2193" len="12,9" str="coordination disorders" />
    <Mention id="M217" section="S3" type="AdverseReaction" start="2185" len="17" str="balance disorders" />
    <Mention id="M218" section="S3" type="Severity" start="2595" len="7" str="serious" />
    <Mention id="M219" section="S3" type="AdverseReaction" start="2603" len="10" str="infections" />
    <Mention id="M220" section="S3" type="AdverseReaction" start="2622" len="6" str="sepsis" />
    <Mention id="M221" section="S3" type="AdverseReaction" start="2622" len="6" str="sepsis" />
    <Mention id="M222" section="S3" type="AdverseReaction" start="2630" len="9" str="pneumonia" />
    <Mention id="M223" section="S3" type="AdverseReaction" start="2630" len="9" str="pneumonia" />
    <Mention id="M224" section="S3" type="AdverseReaction" start="2641" len="10" str="bacteremia" />
    <Mention id="M225" section="S3" type="AdverseReaction" start="2641" len="10" str="bacteremia" />
    <Mention id="M226" section="S3" type="AdverseReaction" start="2653" len="24" str="opportunistic infections" />
    <Mention id="M227" section="S3" type="AdverseReaction" start="2653" len="24" str="opportunistic infections" />
    <Mention id="M228" section="S3" type="AdverseReaction" start="2683" len="24" str="catheter-site infections" />
    <Mention id="M229" section="S3" type="AdverseReaction" start="2683" len="24" str="catheter-site infections" />
    <Mention id="M230" section="S3" type="Severity" start="2775" len="16" str="life-threatening" />
    <Mention id="M231" section="S3" type="AdverseReaction" start="2795" len="5" str="fatal" />
    <Mention id="M232" section="S3" type="AdverseReaction" start="3038" len="20" str="Tumor lysis syndrome" />
    <Mention id="M233" section="S3" type="AdverseReaction" start="3038" len="20" str="Tumor lysis syndrome" />
    <Mention id="M234" section="S3" type="AdverseReaction" start="3060" len="3" str="TLS" />
    <Mention id="M235" section="S3" type="AdverseReaction" start="3060" len="3" str="TLS" />
    <Mention id="M236" section="S3" type="Factor" start="3072" len="3" str="may" />
    <Mention id="M237" section="S3" type="Severity" start="3079" len="16" str="life-threatening" />
    <Mention id="M238" section="S3" type="AdverseReaction" start="3099" len="5" str="fatal" />
    <Mention id="M239" section="S3" type="AdverseReaction" start="3572" len="11" str="Neutropenia" />
    <Mention id="M240" section="S3" type="AdverseReaction" start="3572" len="11" str="Neutropenia" />
    <Mention id="M241" section="S3" type="AdverseReaction" start="3588" len="19" str="febrile neutropenia" />
    <Mention id="M242" section="S3" type="AdverseReaction" start="3588" len="19" str="febrile neutropenia" />
    <Mention id="M243" section="S3" type="Severity" start="3619" len="16" str="life-threatening" />
    <Mention id="M244" section="S3" type="Factor" start="3965" len="9" str="potential" />
    <Mention id="M245" section="S3" type="AdverseReaction" start="3979" len="17" str="neurologic events" />
    <Mention id="M246" section="S3" type="AdverseReaction" start="4008" len="8" str="seizures" />
    <Mention id="M247" section="S3" type="Factor" start="4053" len="4" str="risk" />
    <Mention id="M248" section="S3" type="AdverseReaction" start="4062" len="21" str="loss of consciousness" />
    <Mention id="M249" section="S3" type="Severity" start="4405" len="9" str="transient" />
    <Mention id="M250" section="S3" type="AdverseReaction" start="4415" len="27" str="elevations in liver enzymes" />
    <Mention id="M251" section="S3" type="AdverseReaction" start="4514" len="3" str="CRS" />
    <Mention id="M252" section="S3" type="Severity" start="4671" len="7" str="Grade 3" />
    <Mention id="M253" section="S3" type="AdverseReaction" start="4690" len="27" str="elevations in liver enzymes" />
    <Mention id="M254" section="S3" type="Negation" start="4759" len="7" str="outside" />
    <Mention id="M255" section="S3" type="AdverseReaction" start="4782" len="3" str="CRS" />
    <Mention id="M256" section="S3" type="AdverseReaction" start="5313" len="19" str="leukoencephalopathy" />
  </Mentions>
  <Relations>
    <Relation id="RL1" type="Negated" arg1="M45" arg2="M44" />
    <Relation id="RL2" type="Effect" arg1="M144" arg2="M148" />
    <Relation id="RL3" type="Effect" arg1="M146" arg2="M148" />
    <Relation id="RL4" type="Hypothetical" arg1="M149" arg2="M147" />
    <Relation id="RL5" type="Effect" arg1="M151" arg2="M153" />
    <Relation id="RL6" type="Effect" arg1="M151" arg2="M154" />
    <Relation id="RL7" type="Hypothetical" arg1="M155" arg2="M152" />
    <Relation id="RL8" type="Effect" arg1="M159" arg2="M163" />
    <Relation id="RL9" type="Effect" arg1="M161" arg2="M163" />
    <Relation id="RL10" type="Hypothetical" arg1="M164" arg2="M162" />
    <Relation id="RL11" type="Effect" arg1="M166" arg2="M168" />
    <Relation id="RL12" type="Effect" arg1="M166" arg2="M169" />
    <Relation id="RL13" type="Hypothetical" arg1="M170" arg2="M167" />
    <Relation id="RL14" type="Effect" arg1="M175" arg2="M179" />
    <Relation id="RL15" type="Effect" arg1="M177" arg2="M179" />
    <Relation id="RL16" type="Hypothetical" arg1="M180" arg2="M178" />
    <Relation id="RL17" type="Effect" arg1="M194" arg2="M191" />
    <Relation id="RL18" type="Effect" arg1="M209" arg2="M207" />
    <Relation id="RL19" type="Effect" arg1="M209" arg2="M206" />
    <Relation id="RL20" type="Effect" arg1="M209" arg2="M205" />
    <Relation id="RL21" type="Effect" arg1="M219" arg2="M218" />
    <Relation id="RL22" type="Effect" arg1="M221" arg2="M230" />
    <Relation id="RL23" type="Effect" arg1="M223" arg2="M230" />
    <Relation id="RL24" type="Effect" arg1="M225" arg2="M230" />
    <Relation id="RL25" type="Effect" arg1="M227" arg2="M230" />
    <Relation id="RL26" type="Effect" arg1="M229" arg2="M230" />
    <Relation id="RL27" type="Effect" arg1="M233" arg2="M237" />
    <Relation id="RL28" type="Effect" arg1="M235" arg2="M237" />
    <Relation id="RL29" type="Hypothetical" arg1="M238" arg2="M236" />
    <Relation id="RL30" type="Effect" arg1="M240" arg2="M243" />
    <Relation id="RL31" type="Effect" arg1="M242" arg2="M243" />
    <Relation id="RL32" type="Hypothetical" arg1="M245" arg2="M244" />
    <Relation id="RL33" type="Hypothetical" arg1="M246" arg2="M244" />
    <Relation id="RL34" type="Hypothetical" arg1="M248" arg2="M247" />
    <Relation id="RL35" type="Effect" arg1="M250" arg2="M249" />
    <Relation id="RL36" type="Effect" arg1="M253" arg2="M252" />
    <Relation id="RL37" type="Negated" arg1="M255" arg2="M254" />
  </Relations>
  <Reactions>
    <Reaction id="AR1" str="cytokine release syndrome">
      <Normalization id="AR1.N1" meddra_pt="Cytokine release syndrome" meddra_pt_id="10052015" />
    </Reaction>
    <Reaction id="AR2" str="neurological toxicities">
      <Normalization id="AR2.N1" meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
    </Reaction>
    <Reaction id="AR3" str="infections">
      <Normalization id="AR3.N1" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Reaction>
    <Reaction id="AR4" str="tumor lysis syndrome">
      <Normalization id="AR4.N1" meddra_pt="Tumour lysis syndrome" meddra_pt_id="10045170" meddra_llt="Tumor lysis syndrome" meddra_llt_id="10045152" />
    </Reaction>
    <Reaction id="AR5" str="neutropenia">
      <Normalization id="AR5.N1" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Reaction>
    <Reaction id="AR6" str="febrile neutropenia">
      <Normalization id="AR6.N1" meddra_pt="Febrile neutropenia" meddra_pt_id="10016288" />
    </Reaction>
    <Reaction id="AR7" str="effects on ability to drive">
      <Normalization id="AR7.N1" meddra_pt="Impaired driving ability" meddra_pt_id="10049564" meddra_llt="Driving ability disturbed" meddra_llt_id="10050503" />
    </Reaction>
    <Reaction id="AR8" str="effects on ability to use machines">
      <Normalization id="AR8.N1" flag="unmapped" />
    </Reaction>
    <Reaction id="AR9" str="elevated liver enzymes">
      <Normalization id="AR9.N1" meddra_pt="Hepatic enzyme increased" meddra_pt_id="10060795" meddra_llt="Elevated liver enzymes" meddra_llt_id="10014481" />
    </Reaction>
    <Reaction id="AR10" str="leukoencephalopathy">
      <Normalization id="AR10.N1" meddra_pt="Leukoencephalopathy" meddra_pt_id="10024382" />
    </Reaction>
    <Reaction id="AR11" str="pyrexia">
      <Normalization id="AR11.N1" meddra_pt="Pyrexia" meddra_pt_id="10037660" />
    </Reaction>
    <Reaction id="AR12" str="headache">
      <Normalization id="AR12.N1" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Reaction>
    <Reaction id="AR13" str="peripheral edema">
      <Normalization id="AR13.N1" meddra_pt="Oedema peripheral" meddra_pt_id="10030124" meddra_llt="Peripheral edema" meddra_llt_id="10034570" />
    </Reaction>
    <Reaction id="AR14" str="nausea">
      <Normalization id="AR14.N1" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Reaction>
    <Reaction id="AR15" str="hypokalemia">
      <Normalization id="AR15.N1" meddra_pt="Hypokalaemia" meddra_pt_id="10021015" meddra_llt="Hypokalemia" meddra_llt_id="10021018" />
    </Reaction>
    <Reaction id="AR16" str="tremor">
      <Normalization id="AR16.N1" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Reaction>
    <Reaction id="AR17" str="rash">
      <Normalization id="AR17.N1" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Reaction>
    <Reaction id="AR18" str="constipation">
      <Normalization id="AR18.N1" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Reaction>
    <Reaction id="AR19" str="pneumonia">
      <Normalization id="AR19.N1" meddra_pt="Pneumonia" meddra_pt_id="10035664" />
    </Reaction>
    <Reaction id="AR20" str="sepsis">
      <Normalization id="AR20.N1" meddra_pt="Sepsis" meddra_pt_id="10040047" />
    </Reaction>
    <Reaction id="AR21" str="device-related infection">
      <Normalization id="AR21.N1" meddra_pt="Device related infection" meddra_pt_id="10064687" />
    </Reaction>
    <Reaction id="AR22" str="encephalopathy">
      <Normalization id="AR22.N1" meddra_pt="Encephalopathy" meddra_pt_id="10014625" />
    </Reaction>
    <Reaction id="AR23" str="infection">
      <Normalization id="AR23.N1" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Reaction>
    <Reaction id="AR24" str="overdose">
      <Normalization id="AR24.N1" meddra_pt="Overdose" meddra_pt_id="10033295" />
    </Reaction>
    <Reaction id="AR25" str="confusion">
      <Normalization id="AR25.N1" meddra_pt="Confusional state" meddra_pt_id="10010305" meddra_llt="Confusion" meddra_llt_id="10010300" />
    </Reaction>
    <Reaction id="AR26" str="staphylococcal bacteremia">
      <Normalization id="AR26.N1" meddra_pt="Staphylococcal bacteraemia" meddra_pt_id="10051017" meddra_llt="Staphylococcal bacteremia" meddra_llt_id="10054637" />
    </Reaction>
    <Reaction id="AR27" str="fatal">
      <Normalization id="AR27.N1" meddra_pt="Death" meddra_pt_id="10011906" />
    </Reaction>
    <Reaction id="AR28" str="anemia">
      <Normalization id="AR28.N1" meddra_pt="Anaemia" meddra_pt_id="10002034" meddra_llt="Anemia" meddra_llt_id="10002272" />
    </Reaction>
    <Reaction id="AR29" str="thrombocytopenia">
      <Normalization id="AR29.N1" meddra_pt="Thrombocytopenia" meddra_pt_id="10043554" />
    </Reaction>
    <Reaction id="AR30" str="leukopenia">
      <Normalization id="AR30.N1" meddra_pt="Leukopenia" meddra_pt_id="10024384" />
    </Reaction>
    <Reaction id="AR31" str="diarrhea">
      <Normalization id="AR31.N1" meddra_pt="Diarrhoea" meddra_pt_id="10012735" meddra_llt="Diarrhea" meddra_llt_id="10012727" />
    </Reaction>
    <Reaction id="AR32" str="colitis">
      <Normalization id="AR32.N1" meddra_pt="Colitis" meddra_pt_id="10009887" />
    </Reaction>
    <Reaction id="AR33" str="enteritis">
      <Normalization id="AR33.N1" meddra_pt="Enteritis" meddra_pt_id="10014866" />
    </Reaction>
    <Reaction id="AR34" str="neutropenic colitis">
      <Normalization id="AR34.N1" meddra_pt="Neutropenic colitis" meddra_pt_id="10062959" />
    </Reaction>
    <Reaction id="AR35" str="abdominal pain">
      <Normalization id="AR35.N1" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Reaction>
    <Reaction id="AR36" str="vomiting">
      <Normalization id="AR36.N1" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Reaction>
    <Reaction id="AR37" str="fatigue">
      <Normalization id="AR37.N1" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Reaction>
    <Reaction id="AR38" str="chills">
      <Normalization id="AR38.N1" meddra_pt="Chills" meddra_pt_id="10008531" />
    </Reaction>
    <Reaction id="AR39" str="chest pain">
      <Normalization id="AR39.N1" meddra_pt="Chest pain" meddra_pt_id="10008479" />
    </Reaction>
    <Reaction id="AR40" str="bacterial infections">
      <Normalization id="AR40.N1" meddra_pt="Bacterial infection" meddra_pt_id="10060945" />
    </Reaction>
    <Reaction id="AR41" str="fungal infections">
      <Normalization id="AR41.N1" meddra_pt="Fungal infection" meddra_pt_id="10017533" />
    </Reaction>
    <Reaction id="AR42" str="viral infections">
      <Normalization id="AR42.N1" meddra_pt="Viral infection" meddra_pt_id="10047461" />
    </Reaction>
    <Reaction id="AR43" str="increased alanine aminotransferase">
      <Normalization id="AR43.N1" meddra_pt="Alanine aminotransferase increased" meddra_pt_id="10001551" />
    </Reaction>
    <Reaction id="AR44" str="increased aspartate aminotransferase">
      <Normalization id="AR44.N1" meddra_pt="Aspartate aminotransferase increased" meddra_pt_id="10003481" />
    </Reaction>
    <Reaction id="AR45" str="increased weight">
      <Normalization id="AR45.N1" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Reaction>
    <Reaction id="AR46" str="hypomagnesemia">
      <Normalization id="AR46.N1" meddra_pt="Hypomagnesaemia" meddra_pt_id="10021027" meddra_llt="Hypomagnesemia" meddra_llt_id="10021028" />
    </Reaction>
    <Reaction id="AR47" str="hyperglycemia">
      <Normalization id="AR47.N1" meddra_pt="Hyperglycaemia" meddra_pt_id="10020635" meddra_llt="Hyperglycemia" meddra_llt_id="10020639" />
    </Reaction>
    <Reaction id="AR48" str="decreased appetite">
      <Normalization id="AR48.N1" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Reaction>
    <Reaction id="AR49" str="hypophosphatemia">
      <Normalization id="AR49.N1" meddra_pt="Hypophosphataemia" meddra_pt_id="10021058" meddra_llt="Hypophosphatemia" meddra_llt_id="10021059" />
    </Reaction>
    <Reaction id="AR50" str="back pain">
      <Normalization id="AR50.N1" meddra_pt="Back pain" meddra_pt_id="10003988" />
    </Reaction>
    <Reaction id="AR51" str="pain in extremity">
      <Normalization id="AR51.N1" meddra_pt="Pain in extremity" meddra_pt_id="10033425" />
    </Reaction>
    <Reaction id="AR52" str="bone pain">
      <Normalization id="AR52.N1" meddra_pt="Bone pain" meddra_pt_id="10006002" />
    </Reaction>
    <Reaction id="AR53" str="arthralgia">
      <Normalization id="AR53.N1" meddra_pt="Arthralgia" meddra_pt_id="10003239" />
    </Reaction>
    <Reaction id="AR54" str="resting tremor">
      <Normalization id="AR54.N1" meddra_pt="Resting tremor" meddra_pt_id="10071390" />
    </Reaction>
    <Reaction id="AR55" str="dizziness">
      <Normalization id="AR55.N1" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Reaction>
    <Reaction id="AR56" str="insomnia">
      <Normalization id="AR56.N1" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Reaction>
    <Reaction id="AR57" str="cough">
      <Normalization id="AR57.N1" meddra_pt="Cough" meddra_pt_id="10011224" />
    </Reaction>
    <Reaction id="AR58" str="dyspnea">
      <Normalization id="AR58.N1" meddra_pt="Dyspnoea" meddra_pt_id="10013968" meddra_llt="Dyspnea" meddra_llt_id="10013963" />
    </Reaction>
    <Reaction id="AR59" str="acute respiratory failure">
      <Normalization id="AR59.N1" meddra_pt="Acute respiratory failure" meddra_pt_id="10001053" />
    </Reaction>
    <Reaction id="AR60" str="bronchial hyperactivity">
      <Normalization id="AR60.N1" meddra_pt="Bronchial hyperreactivity" meddra_pt_id="10066091" meddra_llt="Bronchial hyperactivity" meddra_llt_id="10056285" />
    </Reaction>
    <Reaction id="AR61" str="bronchospasm">
      <Normalization id="AR61.N1" meddra_pt="Bronchospasm" meddra_pt_id="10006482" />
    </Reaction>
    <Reaction id="AR62" str="dyspnea exertional">
      <Normalization id="AR62.N1" meddra_pt="Dyspnoea exertional" meddra_pt_id="10013971" meddra_llt="Dyspnea exertional" meddra_llt_id="10013966" />
    </Reaction>
    <Reaction id="AR63" str="respiratory distress">
      <Normalization id="AR63.N1" meddra_pt="Respiratory distress" meddra_pt_id="10038687" />
    </Reaction>
    <Reaction id="AR64" str="respiratory failure">
      <Normalization id="AR64.N1" meddra_pt="Respiratory failure" meddra_pt_id="10038695" />
    </Reaction>
    <Reaction id="AR65" str="wheezing">
      <Normalization id="AR65.N1" meddra_pt="Wheezing" meddra_pt_id="10047924" />
    </Reaction>
    <Reaction id="AR66" str="erythema">
      <Normalization id="AR66.N1" meddra_pt="Erythema" meddra_pt_id="10015150" />
    </Reaction>
    <Reaction id="AR67" str="erythematous rash">
      <Normalization id="AR67.N1" meddra_pt="Rash erythematous" meddra_pt_id="10037855" meddra_llt="Erythematous rash" meddra_llt_id="10015243" />
    </Reaction>
    <Reaction id="AR68" str="generalized rash">
      <Normalization id="AR68.N1" meddra_pt="Rash generalised" meddra_pt_id="10037858" meddra_llt="Generalized rash" meddra_llt_id="10049201" />
    </Reaction>
    <Reaction id="AR69" str="macular rash">
      <Normalization id="AR69.N1" meddra_pt="Rash macular" meddra_pt_id="10037867" meddra_llt="Macular rash" meddra_llt_id="10025418" />
    </Reaction>
    <Reaction id="AR70" str="maculo-papular rash">
      <Normalization id="AR70.N1" meddra_pt="Rash maculo-papular" meddra_pt_id="10037868" meddra_llt="Maculo-papular rash" meddra_llt_id="10025423" />
    </Reaction>
    <Reaction id="AR71" str="papular rash">
      <Normalization id="AR71.N1" meddra_pt="Rash papular" meddra_pt_id="10037876" meddra_llt="Papular rash" meddra_llt_id="10033726" />
    </Reaction>
    <Reaction id="AR72" str="vesicular rash">
      <Normalization id="AR72.N1" meddra_pt="Rash vesicular" meddra_pt_id="10037898" meddra_llt="Vesicular rash" meddra_llt_id="10047377" />
    </Reaction>
    <Reaction id="AR73" str="hypotension">
      <Normalization id="AR73.N1" meddra_pt="Hypotension" meddra_pt_id="10021097" />
    </Reaction>
    <Reaction id="AR74" str="hypertension">
      <Normalization id="AR74.N1" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Reaction>
    <Reaction id="AR75" str="leukocytosis">
      <Normalization id="AR75.N1" meddra_pt="Leukocytosis" meddra_pt_id="10024378" />
    </Reaction>
    <Reaction id="AR76" str="lymphopenia">
      <Normalization id="AR76.N1" meddra_pt="Lymphopenia" meddra_pt_id="10025327" />
    </Reaction>
    <Reaction id="AR77" str="tachycardia">
      <Normalization id="AR77.N1" meddra_pt="Tachycardia" meddra_pt_id="10043071" />
    </Reaction>
    <Reaction id="AR78" str="edema">
      <Normalization id="AR78.N1" meddra_pt="Oedema" meddra_pt_id="10030095" meddra_llt="Edema" meddra_llt_id="10014210" />
    </Reaction>
    <Reaction id="AR79" str="cytokine storm">
      <Normalization id="AR79.N1" meddra_pt="Cytokine storm" meddra_pt_id="10050685" />
    </Reaction>
    <Reaction id="AR80" str="decreased immunoglobulins">
      <Normalization id="AR80.N1" meddra_pt="Immunoglobulins decreased" meddra_pt_id="10021499" meddra_llt="Decreased immunoglobulins" meddra_llt_id="10011969" />
    </Reaction>
    <Reaction id="AR81" str="increased blood bilirubin">
      <Normalization id="AR81.N1" meddra_pt="Blood bilirubin increased" meddra_pt_id="10005364" />
    </Reaction>
    <Reaction id="AR82" str="increased gamma-glutamyl-transferase">
      <Normalization id="AR82.N1" meddra_pt="Gamma-glutamyltransferase increased" meddra_pt_id="10017693" />
    </Reaction>
    <Reaction id="AR83" str="increased liver enzymes">
      <Normalization id="AR83.N1" meddra_pt="Hepatic enzyme increased" meddra_pt_id="10060795" meddra_llt="Elevated liver enzymes" meddra_llt_id="10014481" />
    </Reaction>
    <Reaction id="AR84" str="hypoalbuminemia">
      <Normalization id="AR84.N1" meddra_pt="Hypoalbuminaemia" meddra_pt_id="10020942" meddra_llt="Hypoalbuminemia" meddra_llt_id="10020943" />
    </Reaction>
    <Reaction id="AR85" str="paresthesia">
      <Normalization id="AR85.N1" meddra_pt="Paraesthesia" meddra_pt_id="10033775" meddra_llt="Paresthesia" meddra_llt_id="10033987" />
    </Reaction>
    <Reaction id="AR86" str="aphasia">
      <Normalization id="AR86.N1" meddra_pt="Aphasia" meddra_pt_id="10002948" />
    </Reaction>
    <Reaction id="AR87" str="convulsion">
      <Normalization id="AR87.N1" meddra_pt="Seizure" meddra_pt_id="10039906" meddra_llt="Convulsion" meddra_llt_id="10010904" />
    </Reaction>
    <Reaction id="AR88" str="memory impairment">
      <Normalization id="AR88.N1" meddra_pt="Memory impairment" meddra_pt_id="10027175" />
    </Reaction>
    <Reaction id="AR89" str="cognitive disorder">
      <Normalization id="AR89.N1" meddra_pt="Cognitive disorder" meddra_pt_id="10057668" />
    </Reaction>
    <Reaction id="AR90" str="speech disorder">
      <Normalization id="AR90.N1" meddra_pt="Speech disorder" meddra_pt_id="10041466" />
    </Reaction>
    <Reaction id="AR91" str="disorientation">
      <Normalization id="AR91.N1" meddra_pt="Disorientation" meddra_pt_id="10013395" />
    </Reaction>
    <Reaction id="AR92" str="capillary leak syndrome">
      <Normalization id="AR92.N1" meddra_pt="Capillary leak syndrome" meddra_pt_id="10007196" />
    </Reaction>
    <Reaction id="AR93" str="hypersensitivity reactions">
      <Normalization id="AR93.N1" meddra_pt="Hypersensitivity" meddra_pt_id="10020751" meddra_llt="Hypersensitivity reaction" meddra_llt_id="10020756" />
    </Reaction>
    <Reaction id="AR94" str="hypersensitivity">
      <Normalization id="AR94.N1" meddra_pt="Hypersensitivity" meddra_pt_id="10020751" />
    </Reaction>
    <Reaction id="AR95" str="crs">
      <Normalization id="AR95.N1" meddra_pt="Cytokine release syndrome" meddra_pt_id="10052015" />
    </Reaction>
    <Reaction id="AR96" str="infusion reactions">
      <Normalization id="AR96.N1" meddra_pt="Infusion related reaction" meddra_pt_id="10051792" />
    </Reaction>
    <Reaction id="AR97" str="asthenia">
      <Normalization id="AR97.N1" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Reaction>
    <Reaction id="AR98" str="increased total bilirubin">
      <Normalization id="AR98.N1" meddra_pt="Blood bilirubin increased" meddra_pt_id="10005364" meddra_llt="Bilirubin total increased" meddra_llt_id="10056806" />
    </Reaction>
    <Reaction id="AR99" str="disseminated intravascular coagulation">
      <Normalization id="AR99.N1" meddra_pt="Disseminated intravascular coagulation" meddra_pt_id="10013442" />
    </Reaction>
    <Reaction id="AR100" str="dic">
      <Normalization id="AR100.N1" meddra_pt="Disseminated intravascular coagulation" meddra_pt_id="10013442" meddra_llt="DIC" meddra_llt_id="10012769" />
    </Reaction>
    <Reaction id="AR101" str="cls">
      <Normalization id="AR101.N1" meddra_pt="Capillary leak syndrome" meddra_pt_id="10007196" />
    </Reaction>
    <Reaction id="AR102" str="hemophagocytic lymphohistiocytosis">
      <Normalization id="AR102.N1" meddra_pt="Histiocytosis haematophagic" meddra_pt_id="10048595" meddra_llt="Hemophagocytic lymphohistiocytosis" meddra_llt_id="10071580" />
    </Reaction>
    <Reaction id="AR103" str="macrophage activation syndrome">
      <Normalization id="AR103.N1" meddra_pt="Histiocytosis haematophagic" meddra_pt_id="10048595" meddra_llt="Macrophage activation syndrome" meddra_llt_id="10053867" />
    </Reaction>
    <Reaction id="AR104" str="hlh">
      <Normalization id="AR104.N1" meddra_pt="Histiocytosis haematophagic" meddra_pt_id="10048595" meddra_llt="Hemophagocytic lymphohistiocytosis" meddra_llt_id="10071580" />
    </Reaction>
    <Reaction id="AR105" str="mas">
      <Normalization id="AR105.N1" meddra_pt="Histiocytosis haematophagic" meddra_pt_id="10048595" meddra_llt="Macrophage activation syndrome" meddra_llt_id="10053867" />
    </Reaction>
    <Reaction id="AR106" str="convulsions">
      <Normalization id="AR106.N1" meddra_pt="Seizure" meddra_pt_id="10039906" meddra_llt="Convulsions" meddra_llt_id="10010914" />
    </Reaction>
    <Reaction id="AR107" str="speech disorders">
      <Normalization id="AR107.N1" meddra_pt="Speech disorder" meddra_pt_id="10041466" />
    </Reaction>
    <Reaction id="AR108" str="disturbances in consciousness">
      <Normalization id="AR108.N1" meddra_pt="Altered state of consciousness" meddra_pt_id="10001854" meddra_llt="Consciousness disturbed" meddra_llt_id="10010770" />
    </Reaction>
    <Reaction id="AR109" str="coordination disorders">
      <Normalization id="AR109.N1" meddra_pt="Coordination abnormal" meddra_pt_id="10010947" meddra_llt="Coordination impaired" meddra_llt_id="10010950" />
    </Reaction>
    <Reaction id="AR110" str="balance disorders">
      <Normalization id="AR110.N1" meddra_pt="Balance disorder" meddra_pt_id="10049848" />
    </Reaction>
    <Reaction id="AR111" str="bacteremia">
      <Normalization id="AR111.N1" meddra_pt="Bacteraemia" meddra_pt_id="10003997" meddra_llt="Bacteremia" meddra_llt_id="10003999" />
    </Reaction>
    <Reaction id="AR112" str="opportunistic infections">
      <Normalization id="AR112.N1" meddra_pt="Opportunistic infection" meddra_pt_id="10030901" />
    </Reaction>
    <Reaction id="AR113" str="catheter-site infections">
      <Normalization id="AR113.N1" meddra_pt="Catheter site infection" meddra_pt_id="10056520" />
    </Reaction>
    <Reaction id="AR114" str="tls">
      <Normalization id="AR114.N1" meddra_pt="Tumour lysis syndrome" meddra_pt_id="10045170" meddra_llt="Tumor lysis syndrome" meddra_llt_id="10045152" />
    </Reaction>
    <Reaction id="AR115" str="neurologic events">
      <Normalization id="AR115.N1" meddra_pt="Neurological symptom" meddra_pt_id="10060860" meddra_llt="Neurologic reaction" meddra_llt_id="10029290" />
    </Reaction>
    <Reaction id="AR116" str="seizures">
      <Normalization id="AR116.N1" meddra_pt="Seizure" meddra_pt_id="10039906" meddra_llt="Seizures" meddra_llt_id="10039910" />
    </Reaction>
    <Reaction id="AR117" str="loss of consciousness">
      <Normalization id="AR117.N1" meddra_pt="Loss of consciousness" meddra_pt_id="10024855" />
    </Reaction>
    <Reaction id="AR118" str="elevations in liver enzymes">
      <Normalization id="AR118.N1" meddra_pt="Hepatic enzyme increased" meddra_pt_id="10060795" meddra_llt="Elevated liver enzymes" meddra_llt_id="10014481" />
    </Reaction>
  </Reactions>
</Label>
